推动药物开发的创新，安进公司揭示三大研发方向-117页_136mb

AMGEN Business Review Summary

Core Content

Amgen's business review outlines its strategic direction, financial outlook, and key initiatives for the period through 2030. The company emphasizes its commitment to innovation, biosimilars, and global expansion, while addressing challenges such as price pressure and lifecycle compression.

Main Points

Strategy Overview

• Long-term growth strategy: Amgen aims to deliver sustained revenue growth through a combination of innovative medicines, biosimilars, and efficient manufacturing.
• Capital allocation priorities: The company focuses on maintaining an efficient capital structure to achieve optimal weighted average cost of capital (WACC).
• Shareholder returns: Amgen is committed to returning capital to shareholders through share repurchases and dividends, with a target payout ratio of over 60%.
• Global expansion: Amgen is expanding its geographic presence, particularly in Asia-Pacific, which is expected to be a key growth driver.

Financial Outlook

• 2021 Financial Results:
  • Revenues: $25.979 billion
  • Non-GAAP Net Income: $9,797 million
  • Non-GAAP EPS: $17.10
• 2022 Guidance:
  • Revenues: $25.4B–$26.5B
  • Non-GAAP EPS: $17.00–$18.00
  • Non-GAAP Tax Rate: 13.0%–14.0%
  • Capital Expenditures: ~$950M
• Long-term Guidance (2022–2030):
  • Revenues: Mid-single digit CAGR
  • Non-GAAP Operating Margin: Approximately 50% of product sales
  • Non-GAAP EPS: High-single to low double-digit CAGR

Key Growth Drivers

• Innovative Brands: Products like Repatha® and Otezla® are expected to drive growth through volume increases and label expansions.
• Biosimilars: Amgen's biosimilars business is growing rapidly, with AMJEVITA® expected to be the first U.S. adalimumab biosimilar, launching in January 2023.
• Pipeline: A robust pipeline of new therapies, including LUMAKRAS® (KRAS G12C inhibitor), TEZSPIRE® (severe asthma treatment), and others, is anticipated to augment growth in the latter half of the decade.
• Digital and Operational Innovations: Amgen is leveraging digital innovation, advanced data analytics, and an integrated global to local engagement model to enhance its market position and patient support.

Key Challenges and Risks

• Price Pressure: Amgen is addressing this through volume-driven products and biosimilars.
• Lifecycle Compression: The company is mitigating this by focusing on first-in-class and volume-driven medicines.
• Regulatory and Clinical Risks: Amgen acknowledges the uncertainties in clinical and regulatory developments, as well as potential safety and manufacturing issues.
• Global Health Threats: Pandemics, such as the ongoing COVID-19 outbreak, pose risks to supply chain and commercial operations.
• Market Competition: Amgen faces competition from other companies and biosimilars, and its ability to maintain market leadership is a key concern.

Key Information

Product Highlights

• OTELZA® (apremilast):
  • Has a broad expanded label and is expected to deliver low double-digit average annual sales growth until U.S. loss of exclusivity.
  • Maintains leadership in a competitive psoriasis market.
• TEZSPIRE® (tezepelumab-ekko):
  • Approved for severe asthma, not limited to a specific type.
  • Expected to significantly increase biologic-eligible patient numbers and biologic penetration.
• LUMAKRAS® (sotorasib):
  • First KRAS G12C inhibitor, launched in 2021.
  • Targets a significant population of non-small cell lung cancer (NSCLC) patients.
• AMJEVITA® (adalimumab-atto):
  • First U.S. adalimumab biosimilar, expected to launch in January 2023.
  • Supported by a strong track record of efficacy, safety, and commercial capabilities.

Biosimilars

• Amgen has a growing biosimilars portfolio, with 6 additional candidates beyond AMJEVITA®.
• Biosimilar sales are projected to more than double by 2030 compared to 2021.

Market Position

• Amgen is a leader in the oncology space, with global sales of ~$10 billion in 2021.
• The company has a strong legacy in oncology with successful product launches and industry-leading capabilities.
• Amgen is also a market leader in inflammation and general medicine.

Sustainability and Corporate Responsibility

• Amgen is committed to achieving carbon neutrality by 2027.
• The company emphasizes patient access, safety, and support through various initiatives and programs.

Conclusion

Amgen's strategy is centered on innovation, biosimilars, and global expansion, with a focus on long-term value creation for patients, shareholders, and employees. The company is well-positioned to navigate challenges and capitalize on opportunities, driven by a robust pipeline, strong financial performance, and a commitment to responsible business practices.